Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Georgia
Clinical trial register · United States · industry-sponsored

Clinical Trials in Georgia, 2026

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a US site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors — the full US registry across all sponsors runs to over 22,000 recruiting studies alone.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice — all 9144 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 16 Oct 2026, 03:16 UTC
9144
Studies in scope
industry-sponsored, all four open statuses
4957
Recruiting now
open to new participants
2196
Lead sponsors
across recruiting studies
Top states
California 5309 Florida 4445 Illinois 2491 Georgia 2363 Arizona 2246
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca104 Eli Lilly and Company87 Merck Sharp & Dohme LLC72 AbbVie68 Janssen Research & Development, LLC67
State
California5309 Florida4445 Illinois2491 Georgia2363 Arizona2246
All 51 states
Target enrolment
to

Trials with a site in Georgia

2363 of 9144 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
US states
Start
Not yet open
Alexion Pharmaceuticals, Inc.
Phase 3
1,180
California, Colorado, District of Columbia, Florida, Georgia, Indiana, Massachusetts, Missouri
2027-11-23
Not yet open
HemoSonics LLC
Observational
160
California, Georgia, Pennsylvania
2027-06-25
Not yet open
HemoSonics LLC
Observational
240
California, Georgia, Massachusetts
2027-03-15
Not yet open
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Phase 3
92
Arizona, Colorado, Florida, Georgia, Illinois, Massachusetts, Michigan, Minnesota
2027-02-03
Recruiting
A Pivotal Clinical Study to Evaluate the MySalvia System for the Treatment of Resistant Migraine
NCT07719608Resistant Migraine, Chronic Migraine Headache, Headache (Migraine), Headache, Cluster
Salvia BioElectronics
Not applicable
150
Georgia, Maryland, North Carolina
2026-12-01
Not yet open
AbbVie
Phase 3
520
Arizona, California, Colorado, District of Columbia, Florida, Georgia, Illinois, Massachusetts
2026-11-30
Recruiting
Jazz Pharmaceuticals
Phase 2
50
California, Florida, Georgia, Kentucky, South Carolina
2026-11-30
Not yet open
Usability and Clinical Validation of the Flu A/B/COVID-19 + RSV Multiplex Rapid Test
NCT07875270SARS-CoV-2 Infection, Influenza A, Influenza B, RSV
CorDx, Inc.
Not applicable
1,500
Georgia
2026-11-01
Not yet open
Smith & Nephew, Inc.
Not applicable
330
Colorado, Georgia, Indiana
2026-10-30
Recruiting
TerSera Therapeutics LLC
Phase 1
176
Arkansas, District of Columbia, Florida, Georgia, Illinois, Iowa, Louisiana, Michigan
2026-10-30
Not yet open
Bristol-Myers Squibb
Phase 2
200
Arizona, Arkansas, California, Florida, Georgia, Maryland, Massachusetts, New York
2026-10-30
Not yet open
Boehringer Ingelheim
Phase 1
90
Florida, Georgia, Pennsylvania, Tennessee, Texas
2026-10-26
Not yet open
Novo Nordisk A/S
Phase 3
8,500
Alabama, Arizona, California, Connecticut, Florida, Georgia, Idaho, Illinois
2026-10-26
Not yet open
Lumos Pharma
Phase 1
30
Georgia
2026-10-08
Recruiting
Genmab
Phase 3
600
California, Georgia, Washington
2026-10-07
Recruiting
Hoffmann-La Roche
Phase 3
400
California, Georgia, Michigan, Nevada, New Mexico
2026-10-06
Recruiting
Kallyope Inc.
Phase 3
1,500
Arizona, Arkansas, California, Colorado, Connecticut, Florida, Georgia, Idaho
2026-10-02
Not yet open
Bristol-Myers Squibb
Phase 3
176
Arizona, California, Connecticut, Florida, Georgia, Illinois, Massachusetts, Missouri
2026-10-02
Recruiting
Sanofi
Phase 4
660
California, Florida, Georgia, Illinois, Iowa, Kansas, Louisiana, Maryland
2026-10-01
Recruiting
A Phase 2a Study of SUN-627 in Participants With Non-Active Secondary Progressive and Primary Progressive Multiple Sclerosis (SPMS/PPMS)
NCT07840326Primary Progressive Multiple Sclerosis, Primary Progressive MS, Primary Progressive Multiple Sclerosis (PPMS), Secondary Progressive MS (SPMS)
Sundance Biosciences, Inc.
Phase 2
20
Georgia, North Carolina, Ohio
2026-10
Not yet open
vTv Therapeutics
Phase 2
40
Georgia
2026-10
Recruiting
Medtronic MiniMed, Inc.
Not applicable
1,500
California, Colorado, Connecticut, Florida, Georgia, Idaho, Texas, Virginia
2026-10
Not yet open
Caliway Biopharmaceuticals Co., Ltd.
Phase 3
320
California, Florida, Georgia, Maryland, Nebraska, New York, Ohio, Tennessee
2026-10
Not yet open
Validation of cueStim for Reduction of Freezing of Gait in Parkinson's Disease
NCT07675408Parkinson's Disease With Freezing of Gait
Fortis Medical Devices Limited
Not applicable
60
Florida, Georgia, Kansas, Oregon, Washington
2026-10
Recruiting
Study of EO2002 in Subjects With Corneal Edema Secondary to Corneal Endothelial Dysfunction
NCT07729137Corneal Edema, Fuchs, Fuchs Dystrophy, Fuchs' Endothelial Dystrophy
Emmecell
Phase 2
121
California, Florida, Georgia, Illinois, Indiana, Kansas, Minnesota, Missouri
2026-10
Not yet open
A Study of LY4560736 in Healthy Participants and Participants With Alzheimer's Disease (AD)
NCT07843459Healthy Volunteers, Alzheimer Disease, Amyloid, Plaque, Amyloid
Eli Lilly and Company
Phase 1
111
California, Florida, Georgia, Michigan
2026-10
Recruiting
Fortvita Biologics (USA)Inc.
Phase 1/2
360
Arizona, California, Georgia, New York, Texas
2026-09-30
Recruiting
Novartis Pharmaceuticals
Phase 2
259
Alabama, California, Florida, Georgia, Indiana, Kansas, Louisiana, Michigan
2026-09-29
By invitation
Head Diagnostics
Observational
120
Georgia, Massachusetts
2026-09-28
Recruiting
NervGen Pharma
Phase 3
150
Alabama, Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Georgia
2026-09-28
Recruiting
Eli Lilly and Company
Phase 3
150
Arizona, California, Colorado, Connecticut, Florida, Georgia, Illinois, Indiana
2026-09-25
Recruiting
Acurx Pharmaceuticals Inc.
Phase 2
20
California, Connecticut, Florida, Georgia, Idaho, Illinois, Massachusetts, Michigan
2026-09-25
Not yet open
Flutemetamol F 18 Injection Formulation Comparison
NCT07873463Cognitive Dysfunction
GE Healthcare
Phase 2
20
Florida, Georgia
2026-09-22
Recruiting
Novo Nordisk A/S
Phase 3
650
California, District of Columbia, Florida, Georgia, Illinois, Indiana, Louisiana, Missouri
2026-09-22
Recruiting
Adneuris Therapeutics, Inc.
Phase 3
160
Arizona, California, Colorado, Georgia, Illinois, Maryland, New Jersey, Oklahoma
2026-09-22
Recruiting
Pelage Pharmaceuticals, Inc.
Phase 2/3
600
Alabama, Arkansas, California, Florida, Georgia, Indiana, Louisiana, Minnesota
2026-09-21
Recruiting
Jazz Pharmaceuticals
Phase 2/3
260
Arizona, California, Connecticut, Florida, Georgia, Hawaii, Idaho, Illinois
2026-09-18
Not yet open
Enamel Lesion Detection With New DX Tool
NCT07819370Enamel Lesions, Caries
DrugToothpaste
Colgate Palmolive
Phase 4
5
Georgia
2026-09-15
Not yet open
A Study of KarXT + KarX-EC for Treatment of Irritability in Children and Adolescents With Autism
NCT07284745Irritability Associated With Autism Spectrum Disorder
DrugsKarX-EC·KarXT
Bristol-Myers Squibb
Phase 3
176
Alabama, Arizona, California, Colorado, Florida, Georgia, Illinois, Kentucky
2026-09-11
Recruiting
Medtronic Cardiovascular
Not applicable
1,186
Alabama, Arizona, California, Connecticut, Georgia, Illinois, Minnesota, New York
2026-09-11
Recruiting
Bristol-Myers Squibb
Phase 2
160
District of Columbia, Georgia, Kentucky, Maryland, Mississippi, Nebraska, New York, Ohio
2026-09-10
Recruiting
Takeda
Phase 3
324
Arizona, California, District of Columbia, Florida, Georgia, Massachusetts, Missouri, Montana
2026-09-10
Recruiting
AstraZeneca
Phase 3
200
Arizona, California, Florida, Georgia, Indiana, Louisiana, Maryland, North Carolina
2026-09-10
Recruiting
Johnson & Johnson Vision Care, Inc.
Not applicable
150
Florida, Georgia, Missouri, New York, Rhode Island, Tennessee, Texas, Virginia
2026-09-10
Recruiting
Eli Lilly and Company
Phase 1
179
California, Florida, Georgia, Michigan
2026-09-09
Recruiting
Regeneron Pharmaceuticals
Phase 1
36
Georgia, New Jersey, Oregon
2026-09-08
Recruiting
Pfizer
Phase 3
4,670
Alabama, California, Connecticut, Florida, Georgia, Hawaii, Illinois, Iowa
2026-09-08
Recruiting
Digital STEADI Efficacy
NCT07852650Fall, Mild Cognitive Impairment (MCI), Aging
Friendi.fi Corporation
Phase 1/2
300
Georgia
2026-09-04
Recruiting
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Phase 4
180
California, Florida, Georgia
2026-09-03
Recruiting
Kyowa Kirin, Inc.
Phase 1
72
California, Florida, Georgia, Iowa, Massachusetts, Missouri, New Jersey, New York
2026-09-02
Recruiting
GlaxoSmithKline
Phase 3
54,000
Alabama, Arizona, Arkansas, California, Colorado, Connecticut, Florida, Georgia
2026-09-02
Recruiting
Genentech, Inc.
Phase 4
100
Arizona, Florida, Georgia, Tennessee
2026-09-02
Recruiting
AbbVie
Phase 2
150
California, Georgia
2026-09-01
Recruiting
Polares Medical SA
Not applicable
15
Georgia, New York, Ohio
2026-09-01
Recruiting
AstraZeneca
Phase 3
2,800
Alabama, Arizona, Arkansas, California, District of Columbia, Florida, Georgia, Illinois
2026-09-01
Not yet open
Hypoxic Red Blood Cells in Sickle Cell Anemia
NCT06743113Sickle Cell Anaemia, Sickle Cell Anemia Crisis, Sickle Cell Anemia in Children, Sickle Cell Anemia (HbSS, or HbSβ-thalassemia0)
Hemanext
Not applicable
48
Connecticut, Georgia, Illinois, Maryland, Pennsylvania
2026-09-01
Not yet open
Eli Lilly and Company
Phase 3
170
California, Connecticut, Georgia, Idaho, Kansas, New York, Oklahoma, Pennsylvania
2026-09
Recruiting
Agios Pharmaceuticals, Inc.
Phase 3
54
Georgia, New York, Pennsylvania, Texas
2026-09
Recruiting
Vima Therapeutics
Phase 2
80
Arizona, California, Connecticut, Florida, Georgia, Kansas, Maryland, Michigan
2026-09
Recruiting
Motif Neurotech, Inc.
Not applicable
20
Georgia, Iowa
2026-09
Recruiting
Liquidia Technologies, Inc.
Phase 4
20
Georgia
2026-09
Recruiting
Brexanolone Lifting Outcomes Of Moms
NCT07822321Depression, Postpartum, Postpartum Depression (PPD), Post-partum Depression, Postnatal Depression
Lipocine Inc.
Phase 3
120
Arizona, California, Colorado, Georgia, Idaho, Illinois, Louisiana, Nevada
2026-09
Recruiting
L19IL2/TNF in Patients With Basal Cell Carcinoma
NCT07227870Locally Advanced Basal Cell Carcinoma
DrugDaromun
Philogen S.p.A.
Phase 2
92
Florida, Georgia, New York, Ohio, Texas
2026-09
Not yet open
WATER IV PCa (AS Sub-study)
NCT07650448Localized Prostate Cancer
PROCEPT BioRobotics
Not applicable
333
Arizona, California, Colorado, Florida, Georgia, Idaho, Illinois, Maryland
2026-09
Recruiting
Vaginal Wall Retraction Using VuSleeve
NCT07846527Adult Females
Ceek Women's Health, INC
Observational
500
Colorado, Georgia
2026-09
Recruiting
Geneos Therapeutics
Phase 2
90
Georgia, Louisiana, Maryland, Michigan, New York, Texas, Washington
2026-09
Recruiting
SystImmune Inc.
Phase 3
520
Georgia
2026-09
Recruiting
Agios Pharmaceuticals, Inc.
Phase 3
45
California, Georgia, New York, Pennsylvania, Texas
2026-09
Not yet open
A Study of LY4405094 in Healthy Participants and Participants With Alzheimer's Disease
NCT07787182Healthy Volunteers, Alzheimer Disease, Amyloid, Plaque, Amyloid
DrugLY4405094
Eli Lilly and Company
Phase 1
68
California, Florida, Georgia, Michigan
2026-09
Recruiting
L19IL2/L19TNF in Patients With Cutaneous Squamous Cell Carcinoma
NCT07228442Locally Advanced Cutaneous Squamous Cell Carcinoma
DrugDaromun
Philogen S.p.A.
Phase 2
92
California, Georgia, Massachusetts, North Carolina, Ohio, Texas
2026-09
Recruiting
Ascletis Pharma (China) Co., Limited
Phase 3
3,003
Alabama, Arizona, Arkansas, California, District of Columbia, Florida, Georgia, Idaho
2026-08-31
Recruiting
Novo Nordisk A/S
Phase 3
950
Alabama, California, Colorado, Florida, Georgia, Hawaii, Illinois, Indiana
2026-08-31
Recruiting
Blue Earth Diagnostics
Phase 4
142
California, Georgia, Massachusetts, Missouri, Oregon, Texas
2026-08-31
Recruiting
BioNTech SE
Phase 3
700
Florida, Georgia, Hawaii, Kentucky, Ohio, Pennsylvania, Texas, Utah
2026-08-31
Recruiting
Pfizer
Phase 3
440
California, District of Columbia, Georgia, Iowa, Maryland, Missouri, New York, North Carolina
2026-08-31
Recruiting
Ascletis Pharma (China) Co., Limited
Phase 3
1,560
Alabama, Arizona, Arkansas, California, District of Columbia, Florida, Georgia, Idaho
2026-08-28
Recruiting
A 52-week Study of Remibrutinib in IgE-mediated Food Allergy
NCT07768371IgE-Mediated Food Allergy, Peanut Allergy, Cow Milk Allergy, Egg Allergy
DrugRemibrutinib
Novartis Pharmaceuticals
Phase 3
576
Alabama, Arizona, Arkansas, California, Colorado, Georgia, Illinois, Maryland
2026-08-27
Recruiting
Axsome Therapeutics, Inc.
Phase 3
705
Arkansas, California, Florida, Georgia, Illinois, Indiana, Missouri, New York
2026-08-27
Recruiting
Eli Lilly and Company
Phase 2
120
Alabama, Arizona, California, Florida, Georgia, Illinois, Indiana, Massachusetts
2026-08-27
Recruiting
Eli Lilly and Company
Phase 3
2,001
Alabama, Arizona, California, Connecticut, Florida, Georgia, Idaho, Illinois
2026-08-26
Recruiting
MBX Biosciences
Phase 3
160
Colorado, Florida, Georgia, Louisiana, Mississippi, Nevada, New York, North Carolina
2026-08-26
Not yet open
AstraZeneca
Phase 3
750
Florida, Georgia, Illinois, Michigan, Minnesota, Ohio, Texas, Washington
2026-08-25
Recruiting
A Study to Investigate CV Outcomes With Elecoglipron Compared With Placebo in Adult Participants With HFpEF or HFmrEF
NCT07761117Heart Failure With Preserved Ejection Fraction (HFpEF), Heart Failure With Mildly Reduced Ejection Fraction (HFmrEF)
DrugElecoglipron
AstraZeneca
Phase 3
6,950
Alabama, Alaska, Arizona, California, Colorado, Connecticut, Florida, Georgia
2026-08-24
Recruiting
Novartis Pharmaceuticals
Phase 3
180
Florida, Georgia, Indiana, New York, Ohio, South Carolina, Texas
2026-08-24
Recruiting
Novo Nordisk A/S
Phase 3
1,778
Alabama, Arizona, California, Florida, Georgia, Idaho, Illinois, Indiana
2026-08-24
Recruiting
AstraZeneca
Phase 3
500
California, Florida, Georgia, Illinois, Maryland, Missouri, Nevada, New Jersey
2026-08-24
Recruiting
Pfizer
Phase 3
1,375
Arizona, California, Georgia, Indiana, Michigan, Oklahoma, Pennsylvania, Tennessee
2026-08-24
Recruiting
Boehringer Ingelheim
Phase 3
600
Alabama, Arizona, Arkansas, California, Florida, Georgia, Hawaii, Idaho
2026-08-24
Recruiting
AstraZeneca
Phase 3
7,000
Alabama, Arizona, Arkansas, California, Colorado, Connecticut, Florida, Georgia
2026-08-21
Recruiting
Bristol-Myers Squibb
Phase 1
84
California, Florida, Georgia
2026-08-21
Recruiting
Oruka Therapeutics, Inc.
Phase 2
200
Alabama, California, Connecticut, Georgia, Illinois, Louisiana, Michigan, Minnesota
2026-08-21
Recruiting
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Phase 3
472
Arkansas, California, Florida, Georgia, Illinois, Maryland, Ohio, Oklahoma
2026-08-20
Recruiting
AstraZeneca
Phase 3
1,500
Alabama, Arizona, Arkansas, California, Florida, Georgia, Illinois, Kansas
2026-08-20
Recruiting
AstraZeneca
Phase 3
2,500
Alabama, Arizona, California, Florida, Georgia, Illinois, Iowa, Michigan
2026-08-19
Recruiting
Bausch Health Americas, Inc.
Phase 2
180
Alabama, Arkansas, California, Florida, Georgia, Kansas, Louisiana, Maryland
2026-08-18
Recruiting
Pfizer
Phase 3
375
Alabama, Arizona, California, Florida, Georgia, North Dakota, Texas
2026-08-17
Recruiting
Eli Lilly and Company
Phase 3
1,000
Alabama, Arizona, California, Florida, Georgia, Illinois, Maryland, Massachusetts
2026-08-14
Recruiting
Alkermes, Inc.
Phase 3
150
Florida, Georgia, Michigan, Missouri, North Carolina, Ohio, South Carolina, Texas
2026-08-13
Recruiting
AstraZeneca
Phase 3
600
Alabama, Arizona, California, Colorado, Connecticut, Florida, Georgia, Illinois
2026-08-12
Recruiting
Eli Lilly and Company
Phase 2
150
Alabama, Arizona, California, Connecticut, Florida, Georgia, Illinois, Louisiana
2026-08-12
Recruiting
Genmab
Phase 3
960
Arkansas, California, Georgia, Indiana, Missouri, Washington
2026-08-11
Recruiting
Alveus Therapeutics, Inc.
Phase 2
220
Alabama, Arizona, California, Florida, Georgia, Illinois, Louisiana, Michigan
2026-08-10
Recruiting
Regeneron Pharmaceuticals
Phase 3
15,364
Alabama, Arizona, Arkansas, California, Florida, Georgia, Indiana, Louisiana
2026-08-10
Recruiting
Alkermes, Inc.
Phase 2
312
Arkansas, California, Florida, Georgia, Michigan, Ohio, Rhode Island, South Carolina
2026-08-10
Recruiting
Nektar Therapeutics
Phase 3
510
Alabama, California, Florida, Georgia, Louisiana, Missouri, Nevada, New Jersey
2026-08-07
Recruiting
Novo Nordisk A/S
Phase 3
80
Connecticut, Florida, Georgia, Illinois, Indiana, Iowa, Michigan, New York
2026-08-04
Recruiting
Novo Nordisk A/S
Phase 3
285
Georgia, Hawaii, Illinois, Indiana, Kentucky, North Carolina, South Carolina, Virginia
2026-08-04
Recruiting
Study of NX-5948 Versus Pirtobrutinib in R/R CLL/SLL
NCT07516093B-cell Lymphoma, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
DrugsBexobrutideg·Pirtobrutinib
Nurix Therapeutics, Inc.
Phase 3
620
Georgia, Indiana, Tennessee, Texas, Virginia
2026-08-03
Recruiting
Leal Therapeutics, Inc
Phase 1
90
Arkansas, California, Florida, Georgia, Maryland, New Jersey, Texas
2026-08-03
Recruiting
Kallyope Inc.
Phase 3
1,000
Alabama, Arizona, Arkansas, California, Colorado, Connecticut, Georgia, Illinois
2026-08-03
Recruiting
Sanofi
Phase 1/2
640
Arizona, California, Florida, Georgia, Illinois, Kansas, New York, South Carolina
2026-08-03
Recruiting
VETERANS AFFAIRS AUGUSTA
NCT07776600Chronic Pain
Companion IQ, Inc
Not applicable
200
Georgia
2026-08-01
Not yet open
A Phase 1/2 Study to Evaluate the Safety and Efficacy of Dibotatug (DR-01) in Adults With Bone Marrow Failure Syndromes
NCT07712562Bone Marrow Failure Syndromes, Aplastic Anemias, Severe Aplastic Anemia (SAA), Severe Aplastic Anemia, Relapse
DrugDibotatug
Dren Bio
Phase 1/2
60
California, Florida, Georgia, New York, Ohio, Texas, Virginia, Washington
2026-08
Recruiting
BrainChild Bio, Inc
Phase 2
75
California, Georgia, Illinois, Ohio, Pennsylvania, Washington
2026-08
Recruiting
A Phase 2b Clinical Trial of YN001 in Adults With Coronary Atherosclerosis
NCT07521007Atherosclerosis, Coronary Artery Disease
Beijing Inno Medicine Co., Ltd.
Phase 2
456
Alabama, California, Florida, Georgia, Idaho, Illinois, Kansas, Missouri
2026-07-31
Recruiting
AbbVie
Phase 2
2,000
Alabama, Arizona, California, Colorado, Florida, Georgia, Idaho, Illinois
2026-07-31
Recruiting
A Phase 2 Study to Evaluate the Safety, PD, PK, and Clinical Activity of ADX-097 in Participants With IgAN, LN or C3G
NCT06419205IgA Nephropathy, Lupus Nephritis (LN), C3 (Complement Component 3) Glomerulopathy
Akebia Therapeutics
Phase 2
30
Florida, Georgia, South Carolina
2026-07-30
Recruiting
Gilead Sciences
Phase 2/3
700
California, Connecticut, Florida, Georgia, Missouri, Texas
2026-07-29
Recruiting
Evommune, Inc.
Phase 2
330
Arizona, California, Connecticut, Florida, Georgia, Massachusetts, Michigan, New Jersey
2026-07-29
Recruiting
ReneuRx™ (Nerve Selective Therapy) Utilized in Lateral Hip Pain
NCT07568015Greater Trochanteric Pain Syndrome, Greater Trochanteric Pain Syndrome of Both Lower Limbs, Lateral Hip Pain
DrugTriamcinolone acetate
Brixton Biosciences, Inc.
Not applicable
100
Arizona, Georgia, Louisiana, Massachusetts, New Jersey, Oklahoma, Pennsylvania, Texas
2026-07-27
Recruiting
UCB Biopharma SRL
Phase 2
402
Florida, Georgia, Ohio, Pennsylvania, Texas, Washington
2026-07-27
Recruiting
Autus Valve Continued Access Study (CAS)
NCT07466745Congenital Heart Disease
Edwards Lifesciences
Not applicable
36
California, Colorado, Georgia, Massachusetts, Michigan, New York, North Carolina, Ohio
2026-07-27
Recruiting
AstraZeneca
Phase 1/2
101
California, Colorado, Florida, Georgia, Missouri, New Jersey, Ohio, Tennessee
2026-07-27
Recruiting
Bristol-Myers Squibb
Phase 2
260
California, Colorado, Georgia, Maryland, Massachusetts, Michigan, Minnesota, New York
2026-07-27
Recruiting
Harmony-HHT: ATV-1601 in Participants With Hereditary Hemorrhagic Telangiectasia (HHT)
NCT07601425Hereditary Hemorrhagic Telangiectasia (HHT), Osler Weber Rendu Disease
DrugATV-1601
Atavistik Bio, Inc
Phase 1/2
100
Arizona, Georgia, Indiana, Massachusetts, Minnesota, Utah
2026-07-27
Recruiting
Amgen
Phase 3
3,200
Alabama, California, Connecticut, Florida, Georgia, Hawaii, Idaho, Illinois
2026-07-23
Recruiting
Janssen Research & Development, LLC
Phase 3
348
California, Georgia, Illinois, New York, Washington
2026-07-23
Recruiting
Phase 1/2 Study of Respiratory Syncytial Virus and Human Metapneumovirus (RSV+HMPV) Vaccine Candidate in Adults 60 Years of Age and Older
NCT07734649Respiratory Syncytial Virus Immunization, Human Metapneumovirus Immunization, Healthy Volunteers
DrugHMPV vaccine
Sanofi
Phase 1/2
2,400
Alabama, California, District of Columbia, Florida, Georgia, Illinois, Indiana, Louisiana
2026-07-22
Recruiting
Verastem, Inc.
Phase 2
105
Arizona, California, Florida, Georgia, Illinois, New Jersey, New York, North Carolina
2026-07-22
Recruiting
Gilead Sciences
Phase 1
112
California, District of Columbia, Florida, Georgia, Indiana, Massachusetts, Nevada, New Jersey
2026-07-22
Recruiting
Bayer
Observational
300
Arizona, California, Connecticut, Florida, Georgia, Illinois, Maryland, Massachusetts
2026-07-21
Recruiting
VIATORR® TIPS Study Evaluating 6-10mm Diameters (VIATIPS)
NCT07390344Ascites, Variceal Bleeding, Portal Hypertension Related to Cirrhosis
W.L.Gore & Associates
Observational
152
Georgia, Minnesota, Ohio
2026-07-20
Recruiting
A Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2)
NCT07654374Obesity, Overweight, Chronic Weight Management, Type2 Diabetes Mellitus
DrugAleniglipron
Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics
Phase 3
1,100
Alabama, Arizona, Arkansas, California, Connecticut, Florida, Georgia, Idaho
2026-07-17
Recruiting
Gilead Sciences
Phase 3
590
California, Florida, Georgia, Michigan, Missouri, Texas, Virginia, Washington
2026-07-14
Recruiting
UCB BIOSCIENCES, Inc.
Phase 3
200
Arkansas, Florida, Georgia, Pennsylvania, Texas, Washington
2026-07-14
Recruiting
Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics
Phase 3
3,600
Alabama, Arizona, California, Florida, Georgia, Hawaii, Idaho, Illinois
2026-07-13
Recruiting
Boehringer Ingelheim
Phase 3
390
Arizona, California, Florida, Georgia, Illinois, Maryland, Massachusetts, Minnesota
2026-07-10
Recruiting
Jazz Pharmaceuticals
Phase 3
120
Alabama, California, Colorado, Florida, Georgia, North Carolina, Ohio, Tennessee
2026-07-09
Recruiting
AstraZeneca
Phase 3
600
Arkansas, California, Colorado, Florida, Georgia, Maryland, New York, North Carolina
2026-07-08
Not yet open
Measuring Knee Laxity and Pivot Shift in ACL-Deficient Patients
NCT07688967Anterior Cruciate Ligament (ACL) Tear
Arthroresearch LLC
Observational
25
Georgia
2026-07-07
Recruiting
Evaluation of the FARAFLEX Mapping and Pulsed Field Ablation System in Subjects With Atrial Fibrillation
NCT07575269Paroxysmal Atrial Fibrillation (PAF), Persistent Atrial Fibrillation
Boston Scientific Corporation
Not applicable
571
Arkansas, Georgia, Iowa, New York, Ohio, Pennsylvania, South Carolina, Texas
2026-07-07
Recruiting
AstraZeneca
Phase 3
2,000
Alabama, Arkansas, California, Florida, Georgia, Illinois, Indiana, Iowa
2026-07-06
Recruiting
AstraZeneca
Phase 3
800
Alabama, California, Colorado, Connecticut, Florida, Georgia, Kansas, Kentucky
2026-07-06
Recruiting
Intuitive Surgical
Not applicable
30
Georgia, New York, Washington
2026-07-06
Recruiting
Axsome Therapeutics, Inc.
Phase 3
468
Alabama, Arkansas, California, Florida, Georgia, Kentucky, Massachusetts, Mississippi
2026-07-06
Recruiting
AstraZeneca
Phase 3
1,200
Alabama, Arizona, California, Connecticut, Florida, Georgia, Idaho, Illinois
2026-07-06
Recruiting
AbbVie
Phase 3
531
Alabama, Arizona, California, Florida, Georgia, Illinois, Indiana, Kentucky
2026-07-02
Recruiting
Parasternal Extravascular ICD System Pivotal Clinical Investigation (ALARION EV) Study
NCT07324031Ventricular Arrythmia, Ventricular Fibrillation, Ventricular Tachycardia
AtaCor Medical, Inc.
Not applicable
280
Arizona, Arkansas, California, District of Columbia, Florida, Georgia, Illinois, Kentucky
2026-07-02
Recruiting
Neurocrine Switzerland GmbH
Phase 2
20
California, Colorado, Connecticut, Georgia, Illinois, Indiana, Michigan, Minnesota
2026-07-01
Recruiting
Dompé Farmaceutici S.p.A
Phase 3
272
California, Colorado, Florida, Georgia, Illinois, Kentucky, Maryland, Massachusetts
2026-07-01
Recruiting
Pfizer
Phase 1
120
Colorado, Connecticut, Florida, Georgia, Tennessee
2026-07-01
Recruiting
Kallyope Inc.
Phase 3
1,800
Alabama, Arizona, Arkansas, California, Colorado, Connecticut, Georgia, Illinois
2026-07-01
Not yet open
Shockwave Medical, Inc.
Not applicable
185
Arizona, Colorado, Florida, Georgia, Louisiana, Missouri, New York, North Carolina
2026-07
Recruiting
Pfizer
Phase 2
120
Alabama, California, Georgia, Illinois, Nebraska, New Mexico, Tennessee
2026-06-30
Recruiting
Expedition Therapeutics, Inc
Phase 2
600
Arizona, California, Colorado, Florida, Georgia, Indiana, Kansas, Minnesota
2026-06-30
Recruiting
AbbVie
Phase 2/3
660
California, Florida, Georgia, Missouri, New York, Texas
2026-06-30
Active, closed
Boehringer Ingelheim
Phase 2
344
Alabama, California, Florida, Georgia, Kentucky, Michigan, Missouri, North Carolina
2026-06-30
Recruiting
Nektar Therapeutics
Phase 3
510
Arizona, Arkansas, California, Florida, Georgia, Idaho, Illinois, Kentucky
2026-06-29
Recruiting
AstraZeneca
Phase 3
4,500
Alabama, Arizona, Arkansas, California, Colorado, Connecticut, Florida, Georgia
2026-06-29
Recruiting
Nefro Avillion Clinical Development, LLC
Phase 2
120
California, Florida, Georgia, Massachusetts, Michigan, New Jersey, Texas, Virginia
2026-06-29
Active, closed
Moonlight Therapeutics, Inc.
Phase 1
40
Arkansas, Georgia, Kansas, Michigan, North Carolina
2026-06-29
Recruiting
Biohaven Therapeutics Ltd.
Phase 3
300
Arizona, California, District of Columbia, Florida, Georgia, Illinois, Kansas, Louisiana
2026-06-26
Recruiting
AstraZeneca
Phase 3
750
Arizona, California, Colorado, Connecticut, Florida, Georgia, Illinois, Iowa
2026-06-26
Recruiting
Axsome Therapeutics, Inc.
Phase 3
468
Alabama, Arkansas, California, Florida, Georgia, Kentucky, Massachusetts, Mississippi
2026-06-25
Recruiting
Eli Lilly and Company
Phase 2
150
Alabama, Arizona, California, Connecticut, Florida, Georgia, Illinois, Louisiana
2026-06-25
Recruiting
ViiV Healthcare
Phase 3
564
Arizona, California, Connecticut, District of Columbia, Florida, Georgia, Maryland, Michigan
2026-06-25
Recruiting
A Study to Evaluate TNX-102 SL Monotherapy Versus Placebo in Participants With Major Depressive Disorder (MDD)
NCT07621237Major Depressive Episode (MDE), Major Depressive Disorder (MDD), Depression
DrugCyclobenzaprine
Tonix Pharmaceuticals, Inc.
Phase 2
360
Arizona, California, Florida, Georgia, Illinois, Louisiana, Maryland, Massachusetts
2026-06-25
Recruiting
AstraZeneca
Phase 4
100
Arizona, Arkansas, California, District of Columbia, Florida, Georgia, Idaho, Illinois
2026-06-24
Recruiting
Hoffmann-La Roche
Phase 3
380
California, Connecticut, District of Columbia, Georgia, North Carolina, Ohio, Texas, West Virginia
2026-06-23
Recruiting
Cordis US Corp.
Observational
35
California, Georgia, Michigan, Missouri, Nebraska, Ohio, Pennsylvania, Texas
2026-06-23
Recruiting
Intervention to Help Orient Men to Excel (IN-HOME) Phase II Study
NCT07704060Caregivers, Community Health Workers, Knowledge, Attitude
KDH Research & Communication
Not applicable
360
Georgia
2026-06-19
Active, closed
Antag Therapeutics
Phase 2
150
Arizona, California, Florida, Georgia, Utah
2026-06-19
Active, closed
TScan Therapeutics, Inc.
Phase 3
310
Arizona, California, Colorado, Connecticut, Florida, Georgia, Illinois, Kansas
2026-06-18
Recruiting
PleoPharma, Inc.
Phase 3
420
Arkansas, Connecticut, Florida, Georgia, Kentucky, Maryland, Nevada, New Jersey
2026-06-17
Active, closed
Regeneron Pharmaceuticals
Phase 2
438
Alabama, California, Florida, Georgia, Hawaii, Kentucky, Louisiana, Montana
2026-06-17
Recruiting
AstraZeneca
Phase 3
150
California, Georgia, Illinois, Kentucky, Nevada, South Dakota, Tennessee, Texas
2026-06-15
Recruiting
Gilead Sciences
Phase 2
175
Arizona, California, Colorado, Florida, Georgia, Michigan, Missouri, New Jersey
2026-06-15
Recruiting
A Study of TAK-360 in People With Narcolepsy or Idiopathic Hypersomnia
NCT07646678Idiopathic Hypersomnia, Narcolepsy Type 1, Narcolepsy Type 2
DrugTAK-360
Takeda
Phase 2/3
500
California, Colorado, Florida, Georgia, Michigan, Missouri, New Jersey, North Carolina
2026-06-11
Recruiting
A Phase IIb Study to Evaluate AZD8965 in Participants With IPF.
NCT07652658Idiopathic Pulmonary Fibrosis (IPF)
AstraZeneca
Phase 2
359
Alabama, Arizona, California, Colorado, Florida, Georgia, Idaho, Illinois
2026-06-11
Recruiting
Yarrow Bioscience, Inc.
Phase 2
232
Arizona, California, Florida, Georgia, Kentucky, Michigan, Nebraska, New York
2026-06-10
Recruiting
Study of GB-4362 With Enfortumab Vedotin and Pembrolizumab for Advanced Urothelial Cancer
NCT07484022Advanced Urothelial Cancer, Metastatic Urothelial Carcinoma
DrugsEnfortumab Vedotin·Pembrolizumab
Generate Biomedicines
Phase 1
37
California, Florida, Georgia, Illinois, New Jersey, New York, Texas, Virginia
2026-06-08
Recruiting
Pivotal Open-label Phase 3 Clinical Study of QTX-2101 in Adult Patients With Acute Promyelocytic Leukemia
NCT07504458Acute Promyelocytic Leukemia (APL), Acute Promyelocytic Leukaemia, Acute Promyelocytic Leukemia With PML-RARA, Acute Promyelocytic Leukemia With t(15;17)(q24.1;q21.2); PML-RARA
DrugsArsenic Trioxide·ATRA
Quetzal Therapeutics
Phase 3
150
Alabama, California, Georgia, Kentucky, Maryland, Michigan, New York, North Carolina
2026-06-08
Recruiting
Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma
NCT07562152Pancreatic Cancer, Pancreatic Cancer Metastatic, PDAC, PDAC - Pancreatic Ductal Adenocarcinoma
Immuneering Corporation
Phase 3
510
Alabama, Arizona, California, Colorado, Delaware, Florida, Georgia, Illinois
2026-06-05
Recruiting
GlaxoSmithKline
Phase 1/2
1,456
Georgia, Kansas, Washington
2026-06-05
Recruiting
Rapport Therapeutics Inc.
Phase 3
333
California, Florida, Georgia, Idaho, Indiana, Maryland, New Jersey, New York
2026-06-05
Recruiting
Harmony Biosciences Management, Inc.
Phase 3
258
Alabama, Arizona, California, Colorado, Florida, Georgia, Illinois, Indiana
2026-06-04
Recruiting
Galderma R&D
Not applicable
100
Connecticut, Florida, Georgia, Maryland, Tennessee, Texas
2026-06-03
Recruiting
InventisBio Co., Ltd
Phase 2
75
Alabama, Arizona, California, Florida, Georgia, Idaho, Indiana, Kentucky
2026-06-03
Recruiting
YS Life Science Co., Ltd.
Phase 3
600
California, Florida, Georgia, Kentucky, Missouri, Texas
2026-06-02
Recruiting
AbbVie
Phase 2/3
576
Arizona, California, Colorado, Florida, Georgia, Illinois, Kansas, Maine
2026-06-01
Recruiting
Bayer
Phase 3
117
Colorado, Delaware, Florida, Georgia, Indiana, Massachusetts, Michigan, Missouri
2026-06-01
Recruiting
A Study to Evaluate Safety, Tolerability and Efficacy of AP306 at Fixed Doses in Dialysis Participants With Hyperphosphatemia
NCT06712654Hyperphosphatemia, Chronic Kidney Disease Requiring Chronic Dialysis, End Stage Renal Disease on Dialysis
R1 Therapeutics
Phase 2
168
Alabama, California, Colorado, Connecticut, Florida, Georgia, Michigan, Minnesota
2026-06-01
Not yet open
Evaluation of the Efficacy, Safety, and Tolerability of LevoCept
NCT04457076Contraception, Women at Risk for Pregnancy
Sebela Women's Health Inc.
Phase 3
1,525
California, Colorado, Georgia, Hawaii, Indiana, Minnesota, Missouri, Nevada
2026-06-01
Recruiting
Philogen S.p.A.
Phase 2
180
Florida, Georgia, North Carolina, Ohio, Texas
2026-06-01
Not yet open
Serene Sleep, Inc.
Not applicable
26
California, Georgia
2026-06
Recruiting
Janssen Research & Development, LLC
Phase 3
700
Alabama, Arizona, Arkansas, California, Colorado, Connecticut, Florida, Georgia
2026-05-31
Recruiting
Pfizer
Phase 3
3,230
Alabama, Arkansas, California, Colorado, Florida, Georgia, Idaho, Illinois
2026-05-29
Recruiting
Novartis Pharmaceuticals
Phase 2
120
Alabama, California, Florida, Georgia, Illinois, Kansas, Louisiana, Maryland
2026-05-29
Recruiting
Centessa Pharmaceuticals (UK) Limited
Phase 2/3
222
Alabama, Colorado, Florida, Georgia, Mississippi, North Carolina, Ohio, South Carolina
2026-05-29
Recruiting
Efficacy and Safety of Intravesical TARA-002 Compared With Investigator's Choice of Intravesical Chemotherapy in Participants With BCG-naïve High-grade Non-muscle Invasive Bladder Cancer
NCT07480356Bladder (Urothelial, Transitional Cell) Cancer, Non-Muscle Invasive Bladder Carcinoma, Non-muscle Invasive Bladder Cancer With Carcinoma in Situ
DrugTARA-002
Protara Therapeutics
Phase 3
284
Arizona, Arkansas, California, Georgia, Missouri, South Carolina, Texas
2026-05-29
Recruiting
A Phase 2b Study of the Effects of Camoteskimab in Adults With Moderate-to-Severe Atopic Dermatitis
NCT07599813Atopic Dermatitis, Atopic, Dermatitis, Dermatitis, Atopic
Apollo Therapeutics Ltd
Phase 2
280
Alabama, Arizona, Arkansas, California, Colorado, Florida, Georgia, Idaho
2026-05-28
Recruiting
A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF)
NCT07357727Primary Myelofibrosis (PMF), Post-polycythemia Vera Myelofibrosis (PPV-MF), Post-essential Thrombocythemia Myelofibrosis (PET-MF)
DrugsPelabresib·Ruxolitinib
Novartis Pharmaceuticals
Phase 3
460
Connecticut, Florida, Georgia, Illinois, Indiana, Maryland, New Jersey, New York
2026-05-27
Recruiting
Ono Pharmaceutical Co., Ltd.
Phase 3
250
Florida, Georgia, Maryland, Michigan, New York, Ohio
2026-05-25
Recruiting
Janssen Research & Development, LLC
Phase 3
644
California, Colorado, Florida, Georgia, Kentucky, Louisiana, Michigan, Missouri
2026-05-23
Recruiting
AbbVie
Phase 3
990
Arizona, Arkansas, California, Colorado, Connecticut, Florida, Georgia, Illinois
2026-05-22
Recruiting
Revolution Medicines, Inc.
Phase 3
670
Arizona, Connecticut, Florida, Georgia, Illinois, Maryland, Massachusetts, Minnesota
2026-05-22
Recruiting
Janssen Research & Development, LLC
Phase 3
460
California, Colorado, Florida, Georgia, Kentucky, Louisiana, Michigan, Missouri
2026-05-22
Recruiting
BeOne Medicines
Phase 3
1,056
Alabama, Alaska, Arizona, Arkansas, California, Florida, Georgia, Hawaii
2026-05-22
Recruiting
Kite, A Gilead Company
Phase 3
550
Arizona, California, Colorado, Connecticut, Florida, Georgia, Illinois, Maryland
2026-05-22
Recruiting
Eli Lilly and Company
Phase 3
550
Arizona, California, Florida, Georgia, Idaho, Illinois, Indiana, Iowa
2026-05-22
Recruiting
Takeda
Phase 3
300
Arizona, California, Connecticut, Florida, Georgia, Illinois, Kentucky, Louisiana
2026-05-21
Recruiting
Novo Nordisk A/S
Phase 3
2,500
Alabama, Arizona, Arkansas, California, Colorado, Florida, Georgia, Idaho
2026-05-21
Recruiting
Regeneron Pharmaceuticals
Phase 3
270
Arizona, Georgia, Massachusetts, Michigan, Minnesota, Missouri, New York, Ohio
2026-05-21
Recruiting
Alpha Cognition, Inc
Phase 4
150
California, Florida, Georgia, Illinois, Indiana, Massachusetts, Michigan, Missouri
2026-05-20
Not yet open
Novo Nordisk A/S
Phase 3
1,000
Florida, Georgia, Idaho, Maryland, Michigan, Texas, Virginia
2026-05-20
Recruiting
Incyte Corporation
Phase 2
60
California, District of Columbia, Florida, Georgia, New York, North Carolina, Pennsylvania, Washington
2026-05-20
Recruiting
AbbVie
Phase 1
18
California, Georgia, New York, Tennessee, Texas
2026-05-20
Recruiting
Aspeya, Inc.
Phase 2
108
Arizona, California, Connecticut, Florida, Georgia, Massachusetts, Missouri, Nevada
2026-05-19
Recruiting
Hanmi Pharmaceutical Company Limited
Phase 2
180
Arizona, Florida, Georgia, Indiana, Missouri, Nebraska, Nevada, North Carolina
2026-05-18
Recruiting
Study of [212Pb]Pb-DOTAM-MAM279 ([212Pb]Pb-MP0712) in Patients With Small Cell Lung Cancer and Other DLL3 Expressing Solid Tumors
NCT07278479Large Cell Neuroendocrine Carcinoma, Large Cell Pulmonary Neuroendocrine Carcinoma of the Lung (LCNEC), Extrapulmonary Neuroendocrine Carcinoma (EP-NEC), Small Cell Lung Cancer (SCLC)
Molecular Partners AG
Phase 1/2
138
Florida, Georgia, Maryland, Nebraska, New Jersey, Ohio
2026-05-18
Recruiting
RAI Services Company
Not applicable
1,280
Florida, Georgia, Missouri, North Carolina, Pennsylvania, Texas
2026-05-14
Recruiting
Efficacy, Safety, and Tolerability of Zeleciment Basivarsen (DYNE-101) in Participants With Myotonic Dystrophy Type 1
NCT07486934Myotonic Dystrophy Type 1 (DM1), DM1, Myotonic Dystrophy, Steinert Disease
DrugZeleciment basivarsen
Dyne Therapeutics
Phase 3
150
California, Florida, Georgia, Indiana, Maryland, Missouri, New York, North Carolina
2026-05-14
Recruiting
Draig Therapeutics Ltd
Phase 2
118
Arizona, Arkansas, California, Florida, Georgia, Illinois, Massachusetts, New York
2026-05-14
Recruiting
Ipsen
Phase 3
350
Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Georgia, Illinois
2026-05-14
Recruiting
Eli Lilly and Company
Phase 2
600
Alabama, Arizona, California, Colorado, Florida, Georgia, Indiana, Kentucky
2026-05-13
Recruiting
Efficacy of the Omnipod® 6 System Compared With the Omnipod® 5 System
NCT07579702Type 2 Diabetes Mellitus, Type 1 Diabetes Mellitus
Insulet Corporation
Not applicable
200
California, Colorado, Connecticut, Georgia, Illinois, Indiana, Massachusetts, Michigan
2026-05-13
Recruiting
A Study to Assess the Safety, Tolerability and Efficacy of ION775
NCT07604974Hypertriglyceridemia, Severe Hypertriglyceridemia
Ionis Pharmaceuticals, Inc.
Phase 2
72
California, Colorado, Florida, Georgia, Indiana, Kentucky, Michigan, Ohio
2026-05-12
Recruiting
Dompé Farmaceutici S.p.A
Phase 2
417
Arizona, California, Florida, Georgia, Indiana, Minnesota, Missouri, North Carolina
2026-05-12
Recruiting
Sanofi
Phase 4
300
Arizona, California, Colorado, Florida, Georgia, Illinois, Maryland, Missouri
2026-05-12
Recruiting
Novo Nordisk A/S
Phase 3
5,610
Alabama, Arizona, Arkansas, California, Colorado, District of Columbia, Florida, Georgia
2026-05-11
Recruiting
Pivotal Study of the SUpira System in Patients Undergoing High-Risk Percutaneous COronaRy InTervention (HRPCI)
NCT07296744Coronary Artery Disease, High Risk Percutaneous Coronary Intervention, Interventional Cardiology, Mechanical Circulatory Support
Supira Medical
Not applicable
358
California, Georgia, Illinois, Michigan, Minnesota, Missouri, New Jersey, New York
2026-05-11
Recruiting
Amgen
Phase 3
300
Alabama, Arizona, California, Florida, Georgia, Hawaii, Idaho, Illinois
2026-05-11
Active, closed
A Study of PF-08653945 and PF-08653944 in Adults With Overweight or Obesity
NCT07575932Overweight, Obesity, Overweight and/or Obesity, Overweight or Obesity
DrugsPF-08653945·Berobenatide
Pfizer
Phase 2
940
Arizona, California, Florida, Georgia, Illinois, Kansas, Louisiana, Maryland
2026-05-11
Active, closed
Novartis Pharmaceuticals
Phase 3
5,700
Alabama, Arizona, Arkansas, California, Colorado, Connecticut, Florida, Georgia
2026-05-11
Recruiting
Incyte Corporation
Phase 1
218
Alabama, California, Connecticut, Florida, Georgia, Maryland, Massachusetts, Missouri
2026-05-11
Recruiting
GlaxoSmithKline
Phase 3
1,209
Alabama, California, Florida, Georgia, Illinois, Michigan, Ohio, South Carolina
2026-05-11
Recruiting
Definium Therapeutics US, Inc.
Phase 3
165
Arkansas, California, Colorado, Florida, Georgia, Illinois, Massachusetts, Missouri
2026-05-10
Recruiting
Crystalys Therapeutics
Phase 2
90
Alabama, Arizona, California, Colorado, Florida, Georgia, Illinois, Kentucky
2026-05-08
Recruiting
Novartis Pharmaceuticals
Phase 2
323
California, Florida, Georgia, Illinois, Kansas, Maryland, Michigan, Missouri
2026-05-07
Recruiting
AstraZeneca
Observational
2,150
Arizona, Arkansas, California, Florida, Georgia, Illinois, Kansas, Maryland
2026-05-06
Recruiting
Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII
NCT07326566Glioblastoma (GBM), Newly Diagnosed Glioblastoma, GBM, Glioblastoma Multiforme (GBM)
DrugsTemodar·Temozolomide
Black Diamond Therapeutics, Inc.
Phase 2
162
Alabama, Arkansas, California, Connecticut, District of Columbia, Florida, Georgia, Maryland
2026-05-05
Recruiting
Novo Nordisk A/S
Phase 3
300
Arizona, Florida, Georgia, Illinois, New York, North Dakota, Ohio, Pennsylvania
2026-05-05
Recruiting
Novo Nordisk A/S
Phase 3
300
California, Florida, Georgia, Illinois, New York, Ohio, Pennsylvania, Texas
2026-05-05
Recruiting
Pfizer
Phase 3
2,400
Florida, Georgia, Idaho, Illinois, Kentucky, Louisiana, Massachusetts, New York
2026-05-04
Recruiting
A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors
NCT07488676Gastric or Gastro-esophageal Junction (GEJ) Adenocarcinoma, Pancreatic Adenocarcinoma
DrugXNW27011
Astellas Pharma Global Development, Inc.
Phase 1/2
150
Alabama, California, Florida, Georgia, Indiana, Michigan, New Jersey, New York
2026-05-04
Recruiting
Eli Lilly and Company
Phase 2
60
Arizona, California, Colorado, Florida, Georgia, Illinois, Kansas, Michigan
2026-05-04
Recruiting
Eli Lilly and Company
Phase 2
60
Arizona, California, Colorado, Florida, Georgia, Illinois, Kansas, Michigan
2026-05-04
Active, closed
Bristol-Myers Squibb
Observational
3,000
Georgia
2026-05-01
Recruiting
Delve Bio, Inc.
Not applicable
400
California, Georgia, Maryland, Massachusetts, Tennessee
2026-05-01
Recruiting
Altesa Biosciences, Inc.
Phase 2
180
Alabama, Arizona, California, Florida, Georgia, Illinois, Indiana, Kentucky
2026-05-01
Recruiting
Novel Soluble Epoxide Hydrolase Inhibitor for Neuropathic Pain in Patients With Spinal Cord Injury
NCT06438471Spinal Cord Injuries, Neuropathic Pain, Degenerative Disc Disease, Spinal Stenosis
DrugEC5026
EicOsis Human Health Inc.
Phase 1
36
Georgia
2026-05-01
Recruiting
ALTO-207 in Adults With Treatment-resistant Depression (TRD)
NCT07553637Treatment-resistant Depression (TRD)
Alto Neuroscience
Phase 2
178
Alabama, Arizona, California, Florida, Georgia, Indiana, Maryland, Massachusetts
2026-05
Not yet open
Revive Toric RWE Study
NCT06785194Astigmatism
Bausch & Lomb Incorporated
Observational
30
Florida, Georgia
2026-05
Recruiting
Insulet Corporation
Not applicable
350
California, Colorado, Florida, Georgia, Idaho, Illinois, Indiana, Massachusetts
2026-04-30
Recruiting
Janssen Research & Development, LLC
Phase 3
600
Arkansas, California, Florida, Georgia, Illinois, Maryland, Massachusetts, Nevada
2026-04-30
Recruiting
Athos Therapeutics Inc
Phase 2
120
Florida, Georgia, Ohio
2026-04-30
Recruiting
Oncolytics Biotech
Phase 2
60
Alabama, California, Florida, Georgia, Idaho, Illinois, Indiana, Michigan
2026-04-30
Recruiting
Biomea Fusion Inc.
Phase 2
60
Alabama, California, Florida, Georgia, Nevada, Ohio, Texas, Virginia
2026-04-30
Recruiting
Aquarius Pilot Study to Evaluate the New Axonics Trial System
NCT07335484Urinary Urge Incontinence (UUI), Urinary Frequency (UF), Fecal Incontinence (FI), Overactive Bladder (OAB)
Axonics, Inc.
Not applicable
75
Alabama, Georgia, South Carolina
2026-04-30
By invitation
Axsome Therapeutics, Inc.
Phase 3
300
Arkansas, California, Connecticut, Florida, Georgia, Illinois, Kansas, Kentucky
2026-04-29
Recruiting
Bristol-Myers Squibb
Phase 1
64
Georgia, Texas
2026-04-27
Recruiting
Alnylam Pharmaceuticals
Phase 2
93
California, Florida, Georgia
2026-04-27
Recruiting
Merck Sharp & Dohme LLC
Phase 3
590
District of Columbia, Georgia, Maryland, Massachusetts, Michigan, New Jersey, New York, North Carolina
2026-04-23
Recruiting
LB Pharmaceuticals Inc.
Phase 3
900
Arizona, Arkansas, California, Florida, Georgia, Illinois, Maryland, Missouri
2026-04-23
Recruiting
Minerva Neurosciences
Phase 3
380
California, Florida, Georgia, Maryland, New Jersey, New York, Texas
2026-04-23
Recruiting
Alkermes, Inc.
Phase 3
176
Alabama, Arizona, California, Colorado, Florida, Georgia, Kansas, Massachusetts
2026-04-22
Recruiting
Aurinia Pharmaceuticals Inc.
Phase 4
150
California, Colorado, Florida, Georgia, Louisiana, Maryland, Missouri, Nevada
2026-04-22
Recruiting
Janssen Research & Development, LLC
Phase 3
530
Alabama, California, Colorado, Connecticut, Florida, Georgia, Iowa, Kansas
2026-04-21
Recruiting
RE104 Safety and Efficacy Study in Generalized Anxiety Disorder
NCT07489651Generalized Anxiety Disorder
DrugRE104
Reunion Neuroscience Inc
Phase 2
160
Alabama, Arizona, Arkansas, California, Florida, Georgia, Illinois, Michigan
2026-04-20
Recruiting
A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers
NCT07226843Lymphoma, Non-Hodgkin's, Lymphoma, Diffuse Large B-Cell, Follicular Lymphoma
DrugRituximab
Eli Lilly and Company
Phase 1
460
Arizona, California, Colorado, Florida, Georgia, Massachusetts, Minnesota, New York
2026-04-17
Recruiting
SetPoint Medical Corporation
Not applicable
60
California, Georgia, Maryland, Minnesota, Texas, Washington, West Virginia, Wisconsin
2026-04-17
Recruiting
Immedica Pharma US Inc
Not applicable
100
Georgia
2026-04-17
Recruiting
Visugromab in Cachexia International Trial
NCT07112196Cancer-associated Cachexia
DrugsVisugromab·Visugromab RDE
CatalYm GmbH
Phase 2/3
518
Connecticut, Florida, Georgia, New Jersey, Ohio
2026-04-16
Recruiting
Hoffmann-La Roche
Phase 3
100
Colorado, Connecticut, Florida, Georgia, Missouri, New York, Pennsylvania
2026-04-15
Recruiting
GlaxoSmithKline
Phase 2
200
California, Connecticut, Florida, Georgia, Louisiana, Maryland, Missouri, New Mexico
2026-04-15
Recruiting
Ambros Therapeutics, Inc.
Phase 3
270
Arizona, Arkansas, California, District of Columbia, Florida, Georgia, Illinois, Kansas
2026-04-14
Recruiting
A Study of LY4005130 in Adult Participants With Non-Segmental Vitiligo
NCT07533019Vitiligo, Non-Segmental Vitiligo (NSV)
DrugLY4005130
Eli Lilly and Company
Phase 2
66
Arizona, California, Florida, Georgia, Indiana, Massachusetts, Michigan, New Hampshire
2026-04-14
Recruiting
Regeneron Pharmaceuticals
Phase 2
120
California, Florida, Georgia, Illinois, Kentucky, Michigan, Nebraska, New York
2026-04-14
Recruiting
Novo Nordisk A/S
Phase 3
400
Arizona, California, Connecticut, Florida, Georgia, Idaho, Massachusetts, Nevada
2026-04-13
Recruiting
Incyte Corporation
Phase 3
588
Alabama, Alaska, Arizona, California, Colorado, District of Columbia, Florida, Georgia
2026-04-09
Recruiting
Merck Sharp & Dohme LLC
Phase 3
758
Georgia, Kentucky, Massachusetts, Missouri, New Jersey, New York, Tennessee
2026-04-09
Recruiting
GlaxoSmithKline
Phase 2
420
Alabama, Arizona, California, Colorado, Florida, Georgia, Idaho, Illinois
2026-04-08
Recruiting
Medtronic Cardiac Ablation Solutions
Not applicable
400
Alabama, California, Florida, Georgia, Massachusetts, Missouri, New York, Ohio
2026-04-08
Recruiting
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Phase 3
400
Alabama, Arizona, California, Connecticut, Florida, Georgia, Illinois, Kentucky
2026-04-07
Recruiting
A Gaucher Disease Gene Therapy Trial With FLT201
NCT07223944Gaucher Disease Type 1
Spur Therapeutics
Phase 3
45
California, Colorado, Georgia, Iowa, Minnesota, New Jersey, New York, North Carolina
2026-04-07
Active, closed
Kailera
Phase 2
306
Arizona, California, Connecticut, Florida, Georgia, Illinois, Indiana, Louisiana
2026-04-06
Recruiting
Alkermes, Inc.
Phase 3
150
Alabama, Arizona, California, Colorado, Florida, Georgia, Kansas, Massachusetts
2026-04-06
Recruiting
Regeneron Pharmaceuticals
Phase 3
2,628
Alabama, Arizona, Arkansas, California, Florida, Georgia, Indiana, Louisiana
2026-04-03
Recruiting
Transcend Therapeutics
Phase 3
300
Arizona, Arkansas, California, Colorado, Florida, Georgia, Illinois, Louisiana
2026-04-02
Recruiting
Sanofi
Observational
2,500
Alabama, Arizona, California, Florida, Georgia, Illinois, Kentucky, Maryland
2026-04-01
Recruiting
Palvella Therapeutics, Inc.
Phase 2
15
California, Georgia, Nevada, Texas
2026-04
Recruiting
MiRus
Not applicable
1,025
Georgia
2026-04
Recruiting
MapLight Therapeutics
Phase 2
500
Arkansas, California, Florida, Georgia, Illinois, Maryland, Massachusetts, Michigan
2026-03-31
Recruiting
Merck Sharp & Dohme LLC
Phase 1
40
Alabama, California, Colorado, Florida, Georgia, Illinois, Michigan, Minnesota
2026-03-30
Active, closed
Biomea Fusion Inc.
Phase 2
64
Alabama, California, Florida, Georgia, Nevada, Ohio, Texas, Virginia
2026-03-27
Recruiting
Eisai Inc.
Phase 2
64
California, Florida, Georgia, Maryland, Michigan, North Carolina, South Carolina, Texas
2026-03-26
Recruiting
A Study to Assess the Effects of Zigakibart on IgA Nephropathy.
NCT07146906Immunoglobulin A Nephropathy (IgAN)
DrugZigakibart
Novartis Pharmaceuticals
Phase 2
32
Colorado, Georgia, Iowa, Minnesota
2026-03-26
Recruiting
LB Pharmaceuticals Inc.
Phase 3
456
Arkansas, California, Florida, Georgia, Illinois, Missouri, Ohio
2026-03-25
Recruiting
Merck Sharp & Dohme LLC
Phase 2
100
California, Colorado, Florida, Georgia, Kansas, Louisiana, Missouri
2026-03-24
Recruiting
Continuous Dual Aspiration Technique With Zoom System for Stroke
NCT07491952Ischemic Stroke, Acute Stroke
Imperative Care, Inc.
Observational
750
Alabama, California, Florida, Georgia, Louisiana, Maryland, Minnesota, New York
2026-03-24
Recruiting
Zydus Therapeutics Inc.
Phase 3
386
Georgia, Indiana, Texas
2026-03-24
Recruiting
Novartis Pharmaceuticals
Phase 3
770
Alabama, Arkansas, California, Colorado, Connecticut, District of Columbia, Florida, Georgia
2026-03-24
Active, closed
Eccogene
Phase 2
151
Alabama, California, Florida, Georgia, Minnesota, Nebraska, North Carolina, Ohio
2026-03-23
Recruiting
Hoffmann-La Roche
Phase 3
1,600
Alabama, Arizona, California, District of Columbia, Florida, Georgia, Idaho, Illinois
2026-03-23
Active, closed
ModernaTX, Inc.
Phase 3
4,050
California, Georgia, Idaho, Maryland, Nebraska, Ohio, Rhode Island, South Carolina
2026-03-23
By invitation
Evaluation of the Safety and Performance of a Bioresorbable Nasal Dressing Containing Mometasone Furoate (MF)
NCT07286201Chronic Rhinosinusitis (CRS), Chronic Rhinosinusitis (CRS) With and Without Nasal Polyps
Polyganics BV
Not applicable
110
Colorado, Georgia, Illinois, Louisiana, Maryland, South Carolina, Texas, Utah
2026-03-19
Recruiting
Visugromab, Nivolumab and Lenvatinib Compared to Double Placebo and Lenvatinib in Unresectable or Metastatic Hepatocellular Carcinoma Post Anti-PD-(L)1 Failure
NCT07219459Unresectable or Metastatic Hepatocellular Carcinoma, Child-Pugh A Hepatocellular Carcinoma, Failure of First-Line Treatment That Included an Approved Anti PD-(L)1 Compound
DrugsVisugromab RDE·Opdivo·Lenvatinib·Nivolumab
CatalYm GmbH
Phase 2
104
California, Georgia, Illinois, Massachusetts
2026-03-19
Recruiting
Sanofi
Observational
1,000
Georgia, New York, Utah
2026-03-19
Recruiting
SymBio Pharmaceuticals
Phase 3
180
Arizona, California, Colorado, District of Columbia, Florida, Georgia, Illinois, Indiana
2026-03-17
Recruiting
Gilead Sciences
Observational
3,000
Alabama, California, Colorado, Florida, Georgia, Illinois, Louisiana, Maryland
2026-03-17
Recruiting
Adverum Biotechnologies, Inc.
Phase 3
534
Arizona, Arkansas, California, Colorado, Connecticut, Florida, Georgia, Illinois
2026-03-16
Recruiting
The Use of p48/64 MW HPC Flow Modulation Device in the Treatment of Wide-necked Intracranial Aneurysms
NCT07143019Hemorrhagic Stroke, Aneurysm, Intracranial, Saccular Aneurysm, Fusiform Aneurysm
phenox Inc.
Not applicable
214
Arizona, California, Colorado, Florida, Georgia, Illinois, Iowa, Massachusetts
2026-03-16
Recruiting
Hoffmann-La Roche
Phase 3
2,000
Alabama, Arizona, California, Connecticut, Georgia, Hawaii, Illinois, Kentucky
2026-03-16
Recruiting
Novartis Pharmaceuticals
Phase 2
142
Arkansas, California, Florida, Georgia, Illinois, Missouri
2026-03-16
Recruiting
Bristol-Myers Squibb
Phase 3
850
Alabama, Colorado, Delaware, Florida, Georgia, Illinois, Indiana, Kentucky
2026-03-16
Recruiting
Harmony Biosciences Management, Inc.
Phase 3
248
Alabama, Arizona, California, Colorado, Florida, Georgia, Indiana, Michigan
2026-03-16
Recruiting
Sanofi
Phase 2/3
526
California, Georgia, Illinois, Kansas, Maryland, Massachusetts, Michigan, New York
2026-03-13
Recruiting
Bristol-Myers Squibb
Phase 2/3
690
Arizona, California, Florida, Georgia, Illinois, Iowa, Minnesota, Missouri
2026-03-13
Recruiting
Bristol-Myers Squibb
Phase 3
750
Alabama, Arizona, California, Colorado, Florida, Georgia, Illinois, Indiana
2026-03-12
Recruiting
HeartFlow, Inc.
Observational
5,000
Georgia
2026-03-11
Recruiting
Pfizer
Phase 1/2
132
Arkansas, California, Colorado, Connecticut, District of Columbia, Georgia, Illinois, Maryland
2026-03-11
Recruiting
A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease
NCT07332481Systemic Lupus Erythematosus (SLE), Cutaneous Lupus Erythematosus (CLE)
DrugEnpatoran
EMD Serono Research & Development Institute, Inc.
Phase 3
202
California, Florida, Georgia, Michigan, Texas
2026-03-10
Recruiting
GlaxoSmithKline
Phase 1
225
Alabama, Arkansas, California, Florida, Georgia, Texas, Virginia, Washington
2026-03-09
Recruiting
Janssen Research & Development, LLC
Phase 3
600
California, Colorado, Florida, Georgia, Illinois, Louisiana, Michigan, New Jersey
2026-03-05
Recruiting
Incyte Corporation
Phase 3
700
Alabama, Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Georgia
2026-03-05
Recruiting
Hutchmed
Phase 1/2
186
California, Florida, Georgia, Washington
2026-03-04
Active, closed
Kailera
Phase 2
264
Arizona, California, Florida, Georgia, Illinois, Indiana, Kentucky, Maryland
2026-03-04
Active, closed
LEVEL-2: LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEF-2
NCT07288398Pulmonary Hypertension Associated With HFpEF
DrugTNX-103
Tenax Therapeutics, Inc.
Phase 3
540
Alabama, Arizona, California, Georgia, Illinois, Indiana, Louisiana, Massachusetts
2026-03-03
Recruiting
Janssen Research & Development, LLC
Phase 1
64
California, Georgia, Illinois, Michigan, New York, Texas
2026-03-02
Recruiting
Bactolife A/S
Observational
60
Georgia, Michigan, Minnesota, Wisconsin
2026-03-01
Recruiting
Cocrystal Pharma, Inc.
Phase 1/2
40
Georgia
2026-03-01
Not yet open
BetterMe Limited
Not applicable
300
Georgia
2026-03
Recruiting
Boehringer Ingelheim
Phase 2
30
Arizona, California, Colorado, Florida, Georgia, Iowa, Kansas, Maryland
2026-02-27
Recruiting
AbbVie
Phase 1
127
California, Colorado, Florida, Georgia, Illinois, Michigan
2026-02-27
Recruiting
Bristol-Myers Squibb
Observational
1,500
Arkansas, California, Florida, Georgia, Illinois, Michigan, Minnesota, Nebraska
2026-02-26
Recruiting
Appello Pharmaceuticals, Inc.
Phase 2
150
Arkansas, California, Colorado, Florida, Georgia, Indiana, Kansas, Kentucky
2026-02-25
Recruiting
Novo Nordisk A/S
Phase 3
1,150
Florida, Georgia, Illinois, Indiana, Missouri, New York, North Carolina, Pennsylvania
2026-02-24
Active, closed
Pfizer
Phase 3
1,078
California, Colorado, Florida, Georgia, Maryland, Missouri, Nebraska, New Jersey
2026-02-24
Recruiting
Pfizer
Phase 2
770
Alabama, California, Connecticut, District of Columbia, Florida, Georgia, Hawaii, Missouri
2026-02-23
Recruiting
REVEAL Study - Diagnostic Testing for PTSD Using the Senseye Diagnostic Tool
NCT07280065PTSD - Post Traumatic Stress Disorder
Senseye, Inc.
Phase 3
1,900
Colorado, Georgia, Idaho, Massachusetts, South Carolina
2026-02-23
Recruiting
Clinical Assessment of Response in the Treatment of Depression With Daytime Sleepiness Using Solriamfetol
NCT07484217Major Depressive Disorder With Excessive Daytime Sleepiness Symptoms
DrugSolriamfetol
Axsome Therapeutics, Inc.
Phase 3
508
Arizona, California, Florida, Georgia, Illinois, Maryland, Massachusetts, Nevada
2026-02-23
Recruiting
AstraZeneca
Phase 3
508
Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Georgia, Illinois
2026-02-23
Recruiting
Kyntra Bio
Phase 2
75
Arizona, California, Connecticut, Florida, Georgia, Louisiana, New Mexico, North Carolina
2026-02-22
Active, closed
AURN001 Efficacy in Participants With Corneal Edema Secondary to Corneal Endothelial Dysfunction
NCT07368959Corneal Edema, Corneal Endothelial Dysfunction, Fuchs Endothelial Corneal Dysfunction, Pseudophakic Bullous Keratopathy (PBK)
Aurion Biotech
Phase 3
130
Arizona, Arkansas, Colorado, Georgia, Missouri, North Carolina, Pennsylvania, South Carolina
2026-02-19
Active, closed
Ipsen
Phase 3
1,300
California, Connecticut, District of Columbia, Florida, Georgia, Illinois, Indiana, Louisiana
2026-02-18
Recruiting
C4 Therapeutics, Inc.
Phase 2
100
Alabama, Arizona, California, Florida, Georgia, Indiana, Iowa, Michigan
2026-02-18
Recruiting
Astellas Pharma Global Development, Inc.
Phase 3
614
Arizona, Arkansas, California, Connecticut, Florida, Georgia, Indiana, Kentucky
2026-02-17
Recruiting
Electra Therapeutics Inc.
Phase 1
84
Connecticut, Georgia, Michigan, New York, Ohio, Texas
2026-02-17
Recruiting
Eli Lilly and Company
Phase 2
150
Alabama, Arizona, California, Connecticut, Florida, Georgia, Illinois, Louisiana
2026-02-16
Active, closed
EyePoint Pharmaceuticals, Inc.
Phase 3
240
California, Colorado, Florida, Georgia, Hawaii, Illinois, Indiana, Louisiana
2026-02-16
Recruiting
Merck Sharp & Dohme LLC
Phase 3
900
Alabama, California, Florida, Georgia, Illinois, Indiana, Louisiana, Maine
2026-02-16
Recruiting
Boehringer Ingelheim
Phase 3
286
Alabama, Arizona, California, Colorado, District of Columbia, Florida, Georgia, Illinois
2026-02-16
Recruiting
Amicus Therapeutics
Observational
450
Alabama, Arkansas, Georgia, Missouri, New York, Pennsylvania, Texas, Virginia
2026-02-13
Recruiting
Elion Therapeutics, Inc.
Phase 2
60
Alabama, California, Georgia, Maryland, Massachusetts, Michigan, Missouri, Texas
2026-02-13
Recruiting
Rifaximin 200 mg Plus Oral Rehydration vs Oral Rehydration Alone in Children With Acute Diarrhea
NCT07285785Diarrhea, Gastroenteritis, Bacterial Infection, Acute Diarrhea
DrugRifaximin
Bausch Health Americas, Inc.
Phase 4
54
California, Florida, Georgia, Illinois, Oregon, Texas, Virginia
2026-02-11
Recruiting
Pfizer
Phase 2/3
1,156
Alabama, Arizona, California, Florida, Georgia, Indiana, Kansas, Louisiana
2026-02-11
Recruiting
ViiV Healthcare
Phase 2
186
California, Colorado, Connecticut, Florida, Georgia, Illinois, Kentucky, Missouri
2026-02-11
Recruiting
Eli Lilly and Company
Phase 3
900
Alabama, Arizona, California, Connecticut, Florida, Georgia, Idaho, Illinois
2026-02-10
Recruiting
Pfizer
Phase 1/2
224
Arizona, Arkansas, California, Colorado, Florida, Georgia, Illinois, Massachusetts
2026-02-10
Recruiting
Eli Lilly and Company
Phase 2
450
Arkansas, California, Connecticut, Florida, Georgia, Illinois, Maryland, Massachusetts
2026-02-10
Active, closed
Ocusun Ophthalmic Pharmaceutical (Guangzhou) Co., Ltd.
Phase 2
8
Arizona, California, Colorado, Florida, Georgia, Illinois, North Carolina, North Dakota
2026-02-10
Recruiting
Eli Lilly and Company
Phase 3
800
Alabama, California, Colorado, Florida, Georgia, Louisiana, Maryland, Michigan
2026-02-10
Active, closed
Vaxcyte, Inc.
Phase 3
752
Arizona, Connecticut, Florida, Georgia, Indiana, Kansas, Louisiana, Maryland
2026-02-09
Recruiting
Eli Lilly and Company
Phase 3
900
Alabama, Arizona, California, Colorado, Florida, Georgia, Idaho, Illinois
2026-02-09
Recruiting
Amgen
Phase 3
270
Alabama, Alaska, California, Colorado, Florida, Georgia, Idaho, Illinois
2026-02-09
Recruiting
Eli Lilly and Company
Phase 3
1,000
California, Connecticut, Florida, Georgia, Indiana, Iowa, Maryland, Massachusetts
2026-02-09
Recruiting
i-SENS, Inc.
Not applicable
32
California, Georgia, Washington
2026-02-09
Active, closed
Janssen Research & Development, LLC
Phase 2
168
Alabama, Arizona, California, Colorado, Florida, Georgia, Illinois, Iowa
2026-02-08
Recruiting
Eli Lilly and Company
Phase 3
1,980
Alabama, Arizona, California, Connecticut, Florida, Georgia, Hawaii, Iowa
2026-02-06
Recruiting
Corxel Pharmaceuticals
Phase 2
240
Alabama, California, Florida, Georgia, Illinois, Indiana, Maryland, Massachusetts
2026-02-06
Recruiting
Neurocrine Biosciences
Phase 2
100
Arkansas, California, Florida, Georgia, Nebraska, Ohio, Texas
2026-02-06
Recruiting
C4 Therapeutics, Inc.
Phase 1
60
Arizona, California, Florida, Georgia, Illinois, Indiana, Kentucky, Maryland
2026-02-06
Recruiting
Vima Therapeutics
Phase 2
100
Alabama, Arizona, California, Colorado, Florida, Georgia, Illinois, Kansas
2026-02-05
Recruiting
Janssen Research & Development, LLC
Phase 3
400
Arizona, Arkansas, California, Colorado, Connecticut, Florida, Georgia, Illinois
2026-02-04
Recruiting
AbbVie
Phase 2
195
Alabama, Arizona, Arkansas, California, Florida, Georgia, Illinois, Missouri
2026-02-03
Active, closed
Medtronic MiniMed, Inc.
Not applicable
389
Arkansas, California, Colorado, Connecticut, Florida, Georgia, Idaho, Illinois
2026-02-02
Recruiting
CSL Behring
Phase 2
63
Arkansas, California, Florida, Georgia, Maryland, Mississippi, New York, Ohio
2026-02-02
Recruiting
Incyte Corporation
Phase 2
40
Alabama, Arizona, Connecticut, Florida, Georgia, Illinois, Kansas, Kentucky
2026-02-02
Recruiting
Prilenia
Phase 3
500
Arizona, California, Colorado, Florida, Georgia, Illinois, Kansas, Maryland
2026-02-01
Recruiting
Genmab
Phase 2
240
California, District of Columbia, Florida, Georgia, Montana, Nebraska, New Jersey, New York
2026-01-30
Recruiting
Bausch Health Americas, Inc.
Phase 3
350
Alabama, Arizona, California, Connecticut, District of Columbia, Florida, Georgia, Illinois
2026-01-29
Recruiting
Bristol-Myers Squibb
Phase 3
166
California, Florida, Georgia, Illinois, Massachusetts, New York, Ohio, Tennessee
2026-01-29
Recruiting
Kymera Therapeutics, Inc.
Phase 2
264
California, Colorado, Connecticut, Florida, Georgia, Iowa, Kansas, Kentucky
2026-01-28
Recruiting
Corcept Therapeutics
Phase 2
80
Arizona, California, Florida, Georgia, Indiana, Kansas, Michigan, Minnesota
2026-01-27
Recruiting
Johnson & Johnson Enterprise Innovation Inc.
Phase 1
45
Alabama, California, Florida, Georgia, Massachusetts, New York, North Carolina, Pennsylvania
2026-01-26
By invitation
Immunovant Sciences GmbH
Phase 2
372
Arizona, California, Colorado, Delaware, District of Columbia, Florida, Georgia, Indiana
2026-01-26
Recruiting
Rigicon, Inc.
Not applicable
182
Florida, Georgia, Texas
2026-01-26
Recruiting
Newron Pharmaceuticals SPA
Phase 3
400
California, Florida, Georgia, Maryland, New York
2026-01-23
Recruiting
LB Pharmaceuticals Inc.
Phase 2
320
Arkansas, California, Florida, Georgia, Illinois, Michigan, Missouri, Nevada
2026-01-23
Recruiting
Inobrodib, Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma
NCT07096778Multiple Myeloma Refractory, Multiple Myeloma in Relapse
DrugsPomalidomide·Dexamethasone
CellCentric Ltd.
Phase 2
100
Arizona, California, Florida, Georgia, Illinois, Iowa, Maryland, Massachusetts
2026-01-22
Recruiting
Sanofi
Phase 3
100
Georgia, Nebraska, New Jersey, Texas
2026-01-20
Recruiting
Merck Sharp & Dohme LLC
Phase 3
1,023
Alabama, Alaska, California, Florida, Georgia, Louisiana, Maryland, Minnesota
2026-01-19
Recruiting
Boehringer Ingelheim
Phase 3
400
California, District of Columbia, Florida, Georgia, Idaho, Illinois, Massachusetts, Nevada
2026-01-16
Recruiting
Janssen Research & Development, LLC
Phase 2
240
Arkansas, California, Florida, Georgia, Illinois, Indiana, New Mexico, North Carolina
2026-01-15
Recruiting
Cartography Biosciences
Phase 1
80
Arizona, California, Florida, Georgia, Michigan, Texas, Virginia
2026-01-15
Active, closed
Medtronic Cardiac Ablation Solutions
Not applicable
300
Arkansas, California, Florida, Georgia, Illinois, Kansas, Massachusetts, Minnesota
2026-01-15
Recruiting
Celldex Therapeutics
Phase 3
240
Alabama, Arizona, California, Florida, Georgia, Idaho, Illinois, Kentucky
2026-01-15
Recruiting
Sanofi
Phase 3
160
Alabama, Arizona, California, Colorado, Florida, Georgia, Illinois, Maryland
2026-01-14
Recruiting
Axsome Therapeutics, Inc.
Phase 3
620
Arizona, Arkansas, California, Connecticut, Florida, Georgia, Illinois, Kansas
2026-01-14
Recruiting
Servier Bio-Innovation LLC
Phase 1
30
Georgia, Ohio, Texas
2026-01-14
Recruiting
Renibus Therapeutics, Inc.
Phase 3
150
California, Colorado, Delaware, Florida, Georgia, Idaho, Illinois, Indiana
2026-01-13
Recruiting
Ardelyx
Phase 3
692
Alabama, Arizona, Arkansas, California, Colorado, Florida, Georgia, Idaho
2026-01-13
Recruiting
A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy
NCT07188558Large B-cell Lymphoma, Lymphoma, B-Cell, Relapsed Non-Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma
DrugsRondecabtagene autoleucel·Liso-cel·Axi-cel·Lisocabtagene maraleucel
Lyell Immunopharma, Inc.
Phase 3
400
Arizona, Arkansas, California, Colorado, District of Columbia, Florida, Georgia, Illinois
2026-01-12
Active, closed
Kailera
Phase 3
1,270
Alabama, Arizona, Arkansas, California, Connecticut, Florida, Georgia, Illinois
2026-01-12
Recruiting
BillionToOne Inc.
Observational
1,000
Arizona, California, Florida, Georgia, Louisiana, New York, Texas
2026-01-10
Recruiting
Enveda Therapeutics
Phase 2
50
Alabama, California, Colorado, Florida, Georgia, Illinois, Kansas, Kentucky
2026-01-09
Recruiting
Regeneron Pharmaceuticals
Phase 2
195
Alabama, Arkansas, California, Connecticut, Florida, Georgia, Illinois, Louisiana
2026-01-09
Recruiting
A Study of Buntanetap in Participants With PD
NCT07284784Parkinson's Disease (PD), Deep Brain Stimulation
DrugBuntanetap/posiphen
Annovis Bio Inc.
Phase 2/3
500
Alabama, Arizona, California, Colorado, Connecticut, Florida, Georgia, Indiana
2026-01-09
Recruiting
Janssen Research & Development, LLC
Phase 3
258
Alabama, District of Columbia, Georgia, Illinois, Maryland, Massachusetts, Minnesota, Ohio
2026-01-08
Active, closed
Invivyd, Inc.
Phase 3
1,770
California, Florida, Georgia, Illinois, Kansas, Maryland, Massachusetts, Michigan
2026-01-08
Recruiting
Novo Nordisk A/S
Phase 3
460
California, Florida, Georgia, Idaho, Indiana, Kansas, Louisiana, Maryland
2026-01-08
Recruiting
Amicus Therapeutics
Phase 3
8
Georgia, Minnesota, North Carolina, Ohio, Pennsylvania, Virginia
2026-01-08
Recruiting
AbbVie
Phase 2/3
680
Arizona, California, Colorado, Georgia, Indiana, Minnesota, New York, North Carolina
2026-01-08
Recruiting
Hoffmann-La Roche
Phase 2
120
California, Florida, Georgia, Michigan, Minnesota, Pennsylvania
2026-01-08
By invitation
Medtronic
Observational
2,000
Alabama, California, Colorado, Connecticut, District of Columbia, Florida, Georgia, Indiana
2026-01-07
Recruiting
Disc Medicine, Inc
Phase 1
24
Alabama, California, Georgia, Illinois, Indiana, New York, North Carolina, Ohio
2026-01-06
Recruiting
Syndeio Biosciences, Inc
Phase 2
164
Arizona, California, Florida, Georgia, Illinois, Louisiana, Maryland, Massachusetts
2026-01-05
Recruiting
Regeneron Pharmaceuticals
Phase 3
915
Georgia, New York, Ohio, Texas
2026-01-02
Recruiting
Alpha Radiation Emitters Device (DaRT) for the Treatment of Cutaneous SCC for Immunocompromised Patients
NCT06615635Squamous Cell Carcinoma, Alpha Radiation, Immunocompromised, Carcinoma, Squamous
Alpha Tau Medical LTD.
Not applicable
28
Arizona, Florida, Georgia, Minnesota, New York
2026-01-01
Recruiting
Acepodia Biotech, Inc.
Phase 1/2
34
Georgia, Massachusetts
2026-01-01
Recruiting
Theradex
Phase 2
66
Florida, Georgia, Minnesota, Texas
2026-01-01
Not yet open
Greg Bew
Phase 2
100
Georgia
2026-01-01
Recruiting
Bristol-Myers Squibb
Phase 2/3
990
Arizona, Arkansas, California, Florida, Georgia, Illinois, Indiana, Iowa
2025-12-31
Recruiting
Post-Market Study of the Signia Circular Stapler With Tri-Staple Technology in Left-sided Colon, Sigmoid, and Rectal Resections
NCT07351071Colorectal Anastomosis, Left-sided Colon Resection, Anastomotic Leak, Anastomotic Complication
Medtronic - MITG
Not applicable
137
Connecticut, Florida, Georgia, Massachusetts, Minnesota, North Carolina, Ohio, Pennsylvania
2025-12-30
Active, closed
Kailera
Phase 3
1,270
Arizona, Arkansas, California, Connecticut, Florida, Georgia, Illinois, Kansas
2025-12-30
Active, closed
UCB Biopharma SRL
Phase 2
165
California, Florida, Georgia, Illinois, Indiana, Kentucky, Michigan, Nebraska
2025-12-29
Recruiting
Sanofi
Phase 2
144
Arizona, California, Florida, Georgia, Illinois, Indiana, Kansas, Kentucky
2025-12-29
Recruiting
Aconcagua Bio, Inc. a wholly owned subsidiary of Structure Therapeutics
Phase 1/2
164
California, Georgia, Minnesota, Missouri, Texas
2025-12-29
Recruiting
Study of GVV858 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors
NCT07288359Advanced HR+/HER2- Breast Cancer, Advanced CCNE1-amplified Solid Tumors, Metastatic Castration-resistant Prostate Cancer
DrugsLetrozole·Fulvestrant
Novartis Pharmaceuticals
Phase 1/2
205
Georgia, Tennessee, Texas
2025-12-29
Recruiting
Neurocrine Biosciences
Phase 2
150
Arkansas, California, Florida, Georgia, Maryland, New Jersey, New York, Texas
2025-12-24
Recruiting
Enveda Therapeutics
Phase 2
105
Alabama, Arkansas, California, Florida, Georgia, Illinois, Indiana, Kentucky
2025-12-22
Recruiting
Tyra Biosciences, Inc
Phase 2
230
California, Florida, Georgia, Illinois, Indiana, Massachusetts, Michigan, Missouri
2025-12-22
Recruiting
Taiho Oncology, Inc.
Phase 3
360
Alaska, California, District of Columbia, Florida, Georgia, Illinois, Michigan, New Jersey
2025-12-22
Recruiting
Protalix
Phase 2
150
Arizona, Arkansas, California, Florida, Georgia, Michigan, Pennsylvania, Texas
2025-12-22
Recruiting
Janssen Research & Development, LLC
Phase 3
800
Arizona, Arkansas, California, Colorado, Florida, Georgia, Illinois, Kansas
2025-12-19
Active, closed
Pfizer
Phase 3
3,578
Arizona, California, Colorado, Florida, Georgia, Maryland, Missouri, Nebraska
2025-12-19
Active, closed
Amgen
Phase 3
250
California, Florida, Georgia, New York, North Carolina, Ohio, Texas, Washington
2025-12-19
Recruiting
Merck Sharp & Dohme LLC
Phase 2/3
570
California, Colorado, District of Columbia, Florida, Georgia, Illinois, Michigan, Missouri
2025-12-18
Active, closed
Kailera
Phase 3
2,530
Alabama, Arizona, California, Colorado, Connecticut, Florida, Georgia, Illinois
2025-12-18
Recruiting
AbbVie
Phase 2
195
Alabama, Arizona, Arkansas, California, Florida, Georgia, Illinois, Nevada
2025-12-18
Recruiting
Draig Therapeutics Ltd
Phase 2
300
Arkansas, California, Florida, Georgia, Maryland, Massachusetts, Mississippi, Nevada
2025-12-16
Recruiting
Neurocrine Biosciences
Phase 3
560
California, Florida, Georgia, Massachusetts, Mississippi, New Jersey, New York, Texas
2025-12-16
Recruiting
AstraZeneca
Phase 2
320
Arizona, California, Colorado, Florida, Georgia, Illinois, Louisiana, Maryland
2025-12-15
Recruiting
Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)
NCT07252232Pancreatic Cancer, PDAC, PDAC - Pancreatic Ductal Adenocarcinoma, Resectable Pancreatic Ductal Adenocarcinoma (PDAC)
DrugCetuximab
Revolution Medicines, Inc.
Phase 3
500
Arizona, California, Colorado, Connecticut, Florida, Georgia, Indiana, Kansas
2025-12-15
Recruiting
Eli Lilly and Company
Phase 3
1,035
Alabama, Arizona, California, Colorado, Connecticut, Florida, Georgia, Hawaii
2025-12-15
Recruiting
Eccogene
Phase 2
160
Arizona, Arkansas, California, Florida, Georgia, Illinois, Indiana, Louisiana
2025-12-15
Recruiting
A Long-term Follow-up Study in Patients Who Received BEAM-101
NCT07373639Hemoglobinopathy, Sickle Cell Disease
Beam Therapeutics Inc.
Observational
50
Alabama, Arizona, Florida, Georgia, Massachusetts, Michigan, Minnesota, Missouri
2025-12-15
Recruiting
Medtronic Neurovascular Clinical Affairs
Observational
118
Florida, Georgia, Illinois, Indiana, Iowa, Michigan, Missouri, South Carolina
2025-12-12
Recruiting
Ascendis Pharma A/S
Phase 3
186
California, Colorado, Delaware, District of Columbia, Florida, Georgia, Idaho, Louisiana
2025-12-12
Recruiting
Pfizer
Phase 3
800
Arizona, Arkansas, California, Colorado, Connecticut, Florida, Georgia, Idaho
2025-12-11
Recruiting
A Study to Evaluate Atumelnant in Adults With Congenital Adrenal Hyperplasia
NCT07144163Congenital Adrenal Hyperplasia, Classic Congenital Adrenal Hyperplasia
DrugAtumelnant
Crinetics Pharmaceuticals Inc.
Phase 3
150
California, Colorado, Florida, Georgia, Illinois, Maryland, Michigan, Minnesota
2025-12-11
Recruiting
Shionogi
Phase 2
192
California, Florida, Georgia, Massachusetts, Missouri, New York, North Carolina, Ohio
2025-12-11
Recruiting
GT Medical Technologies, Inc.
Phase 3
766
Arizona, California, Florida, Georgia, Maryland, New Hampshire, New Jersey, New York
2025-12-10
Recruiting
A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder
NCT06793397Major Depressive Disorder (MDD), Depression in Adults, Depression - Major Depressive Disorder, Depression Disorders
DrugCYB003
Cybin IRL Limited
Phase 3
330
Alabama, Arizona, Arkansas, California, Connecticut, Florida, Georgia, Illinois
2025-12-10
Recruiting
Pfizer
Phase 3
32,500
Alabama, Arizona, Arkansas, California, District of Columbia, Florida, Georgia, Illinois
2025-12-10
Recruiting
AstraZeneca
Phase 2
230
Arizona, California, Connecticut, Florida, Georgia, Idaho, Illinois, Kentucky
2025-12-10
Recruiting
Incyte Corporation
Phase 3
466
Alaska, Arizona, California, Colorado, Florida, Georgia, Illinois, Kentucky
2025-12-09
Active, closed
Boehringer Ingelheim
Phase 3
135
Alabama, California, Florida, Georgia, Illinois, Indiana, Kentucky, Maryland
2025-12-09
Recruiting
Ensysce Biosciences
Phase 3
320
Georgia, Texas, Utah
2025-12-09
Active, closed
AstraZeneca
Phase 2
222
Arizona, Florida, Georgia, Illinois, Kansas, North Carolina, Ohio, Pennsylvania
2025-12-05
Recruiting
AstraZeneca
Phase 3
1,100
Alabama, Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Georgia
2025-12-04
Recruiting
Akebia Therapeutics
Phase 2
60
California, Colorado, Florida, Georgia, Illinois, Kentucky, Massachusetts, Michigan
2025-12-03
Recruiting
Janssen Research & Development, LLC
Phase 3
500
Arizona, California, Connecticut, Florida, Georgia, Illinois, Kentucky, Maryland
2025-12-03
Recruiting
Generate Biomedicines
Phase 3
786
California, Colorado, Florida, Georgia, Illinois, Maryland, Michigan, Mississippi
2025-12-03
Recruiting
Bristol-Myers Squibb
Phase 3
366
Alabama, Arizona, California, Colorado, Florida, Georgia, Idaho, Indiana
2025-12-03
Recruiting
Sanofi
Phase 2
37
California, District of Columbia, Georgia, Massachusetts, New York, Texas, Washington
2025-12-02
Active, closed
Novartis Pharmaceuticals
Phase 2
234
Alabama, Arkansas, California, Florida, Georgia, Illinois, Louisiana, Maryland
2025-12-02
Recruiting
Bristol-Myers Squibb
Phase 3
650
Arizona, California, Florida, Georgia, Maryland, Massachusetts, Michigan, Minnesota
2025-12-02
By invitation
Research Study for Patients With Neurological Diseases Which Evaluates the Patient Experience of the MemorEM Device
NCT07222605Alzheimer Disease, Parkinson Disease, Frontotemporal Dementia, Cortico Basal Degeneration
eQ8Health Corporation d/b/a CareONE Concierge
Not applicable
1,000
Georgia
2025-12-01
Recruiting
Dompé Farmaceutici S.p.A
Phase 3
153
Florida, Georgia, Missouri, New York, North Carolina, Tennessee, Texas
2025-12-01
Active, closed
Vaxcyte, Inc.
Phase 3
4,049
Alabama, Arizona, California, Florida, Georgia, Indiana, Kansas, Louisiana
2025-12-01
Recruiting
Trial Against INtractable Type 2 Diabetes (CAPTAIN-T2D)
NCT07296484Type 2 Diabetes, Cortisol Excess
DrugClofutriben
Sparrow Pharmaceuticals
Phase 2
1,500
Arizona, California, Florida, Georgia, Idaho, Illinois, Iowa, Kansas
2025-11-29
Recruiting
A Study to Evaluate LY3537021 for the Treatment of Nausea and Vomiting Caused by Chemotherapy in Adults With Cancer
NCT07169851Nausea, Vomiting, Drug-Related Side Effects and Adverse Reactions, Neoplasms
Eli Lilly and Company
Phase 2
204
California, Colorado, Florida, Georgia, Illinois, Indiana, Mississippi, New York
2025-11-28
Recruiting
Genmab
Phase 3
660
Alabama, Arizona, California, Connecticut, District of Columbia, Florida, Georgia, Illinois
2025-11-28
Recruiting
Amgen
Phase 3
750
Arizona, California, Colorado, Connecticut, Delaware, Florida, Georgia, Illinois
2025-11-28
Active, closed
ModernaTX, Inc.
Phase 4
30,000
Alabama, Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Georgia
2025-11-26
Active, closed
A Study to Investigate Safety and Effectiveness of CRN09682 in Participants With SST2-Expressing NENs and Other Solid Tumors
NCT07129252SST2-positive Neuroendocrine Neoplasms, Neuroendocrine Tumors, Neuroendocrine Neoplasm
Crinetics Pharmaceuticals Inc.
Phase 1/2
150
Arizona, California, Colorado, Connecticut, Georgia, Kentucky, Louisiana, Michigan
2025-11-26
Recruiting
Jazz Pharmaceuticals
Phase 1
100
Arizona, California, Connecticut, Florida, Georgia, Illinois, Maryland, Michigan
2025-11-26
By invitation
Soleno Therapeutics, Inc.
Observational
200
Arizona, California, Colorado, Florida, Georgia, Illinois, Indiana, Massachusetts
2025-11-26
By invitation
Celldex Therapeutics
Phase 3
1,370
Alabama, Arizona, California, Colorado, Florida, Georgia, Illinois, Indiana
2025-11-25
Active, closed
Amgen
Phase 3
250
California, Florida, Georgia, New York, North Carolina, Ohio, Texas, Washington
2025-11-25
Recruiting
Kuros Biosurgery AG
Not applicable
126
California, Colorado, Georgia, North Carolina, Pennsylvania, Tennessee, Virginia
2025-11-25
Recruiting
SAb Biotherapeutics, Inc.
Phase 2
159
California, Colorado, Florida, Georgia, Indiana, Massachusetts, Missouri, New Mexico
2025-11-25
Recruiting
Eli Lilly and Company
Phase 2
400
California, Connecticut, Florida, Georgia, Iowa, Maryland, Massachusetts, Pennsylvania
2025-11-24
Recruiting
Hoffmann-La Roche
Phase 3
900
Alabama, Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Georgia
2025-11-24
Recruiting
Mirum Pharmaceuticals, Inc.
Phase 2
60
Arizona, California, Colorado, Florida, Georgia, Illinois, Maryland, Massachusetts
2025-11-22
Recruiting
Neurotech Pharmaceuticals
Phase 4
234
California, Colorado, Florida, Georgia, Illinois, Maryland, Massachusetts, Michigan
2025-11-21
Active, closed
Efficacy and Safety of NVX-CoV2705
NCT07086222COVID-19, Sars-CoV-2 Infection
Novavax
Phase 4
6,500
Alabama, Arizona, California, Colorado, Connecticut, Florida, Georgia, Idaho
2025-11-20
Recruiting
Bayer
Phase 3
111
Colorado, Delaware, Florida, Georgia, Indiana, Massachusetts, Michigan, Missouri
2025-11-19
Active, closed
Carcinoid Syndrome Efficacy Study Featuring an Oral Daily Paltusotine Regimen
NCT07087054Carcinoid Syndrome, Carcinoid, Carcinoid Tumor, Carcinoid Tumor of Ileum
Crinetics Pharmaceuticals Inc.
Phase 3
141
Arizona, California, Connecticut, Florida, Georgia, Iowa, Kentucky, Louisiana
2025-11-19
Active, closed
Phase 2a Study of VX-407 in Participants With ADPKD Who Have a Subset of PKD1 Gene Variants (AGLOW)
NCT07161037Autosomal Dominant Polycystic Kidney Disease (ADPKD)
DrugVX-407
Vertex Pharmaceuticals Incorporated
Phase 2
26
Alabama, California, Connecticut, Florida, Georgia, Illinois, Iowa, Kansas
2025-11-19
Active, closed
Bayer
Phase 2
60
Alabama, Florida, Georgia, Idaho, Massachusetts, Texas
2025-11-19
Recruiting
Summit Therapeutics
Phase 3
600
Alabama, Arizona, California, Colorado, Connecticut, Delaware, Florida, Georgia
2025-11-18
Recruiting
Sanofi
Observational
1,000
Alabama, Arizona, California, Colorado, Florida, Georgia, Illinois, Michigan
2025-11-17
Recruiting
A Multicenter, Prospective Blood Collection Study in a Kidney Transplant Population
NCT07006831Kidney Disease, Kidney Transplant, Transplant Recipient, Renal Function
Devyser Inc.
Observational
400
California, Georgia, Maryland, Massachusetts, Utah
2025-11-14
Active, closed
Pfizer
Phase 2
128
Arizona, Arkansas, California, Florida, Georgia, Illinois, Indiana, Kansas
2025-11-13
Recruiting
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics (PK) of EVOLVE104 in Participants With Advanced Urothelial and Squamous Cell Carcinomas
NCT07217171Bladder Cancer, Squamous Cell Carcinoma of the Lung, Esophageal Squamous Cell Carcinoma, Tongue Squamous Cell Carcinoma
EvolveImmune United, Inc
Phase 1
160
California, Connecticut, Georgia, Michigan, New York, North Carolina, Ohio, Pennsylvania
2025-11-13
Recruiting
Incyte Corporation
Phase 2
160
Alabama, California, District of Columbia, Florida, Georgia, Indiana, Iowa, Kentucky
2025-11-12
Recruiting
Neuren Pharmaceuticals Limited
Phase 3
160
Alabama, California, District of Columbia, Georgia, Illinois, Maryland, Massachusetts, Michigan
2025-11-12
Active, closed
Hoffmann-La Roche
Phase 3
1,060
Arizona, California, Connecticut, Florida, Georgia, Illinois, Massachusetts, Michigan
2025-11-12
Rows per page Showing 1–500 of 2363
1 2 3 Next
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a US investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 16 October 2026. https://priyalifescience.com/clinical-trials-usa/state/georgia

Query this register directly
GET /api/trials?country=usa&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every industry-sponsored study on the registry that lists at least one investigative site in the US and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 9,144 studies in total at the last sync on 16 Oct 2026, 03:16 UTC. Academic and other non-industry sponsors are out of scope by design. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 2,363 of those studies with a site in Georgia.

How many clinical trials are recruiting in Georgia?

1,204 of the 2,363 studies on this page are recruiting new participants as of the 16 Oct 2026, 03:16 UTC sync. A further 36 have not yet opened recruitment, 1,064 are active but closed to new participants, and 59 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Georgia), 2,363 studies
PhaseStudiesRecruitingShare
Phase 396246140.7%
Phase 244923419%
Not applicable28913112.2%
Observational190958%
Phase 1165977%
Phase 1/2159966.7%
Phase 2/383493.5%
Phase 466412.8%

Most active sponsors

Lead sponsors with the most studies (Georgia)
Lead sponsorStudiesRecruiting
AstraZeneca10458
Eli Lilly and Company8749
Merck Sharp & Dohme LLC7229
AbbVie6829
Janssen Research & Development, LLC6730
Novartis Pharmaceuticals6430
Bristol-Myers Squibb4927
Pfizer4931
Sanofi4827
Hoffmann-La Roche4618
Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the US Pharma Salary Guide, see who's behind them in the US Company Directory, or track approvals on the FDA Approvals Tracker. For Irish, UK and EU sites, see the Ireland, UK and EU registers.